中药灌注栓塞为主综合治疗原发性肝癌的临床研究

目的 研究中药抗癌制剂灌注栓塞为主、中医辨证施治为辅的综合治疗方法对原发性肝癌的治疗效果和毒副反应。方法 41例肝癌患者分为治疗组和对照组。治疗组(18例)予莪术油微球和华蟾素、艾迪注射液、碘化油等经肝动脉灌注栓塞；对照组(23例)给予化学治疗药物和碘化油等灌注栓塞，两组同时给予中医辨证施治。结果 治疗组、对照组稳定率分别为77．78％、69．57％，差异无显著性。治疗后乏力、食欲不振改善情况，治疗组优于对照组(P<0．05)。两组6、12、24个月的生存率分别为：61．11％和56．52％、27．78％和30．43％、22．22％和26．09％，差异无显著性。治疗前后的白细胞下降、血小板下降、血红蛋白下降和恶心呕吐等毒副反应，治疗组的发生率均低于对照组，其中白细胞下降、恶心呕吐差异有显著性(P<0．05)。结论 中药抗癌制剂灌注栓塞为主的综合治疗方法对原发性肝癌有较好的近期疗效，毒副反应轻，患者耐受性好。其远期疗效有待进一步观察。

Clinical Study on Comprehensive Treatment of Primary Liver Cancer Mainly with Chinese Medicinal Perfusion/Embolization

ObjectiveTo study the clinical efficacy and adverse reaction of comprehensive therapy mainly with Chinese anti-cancer medicinal perfusion/embolization and assisted with Chinese drug-therapy based on TCM Syndrome Differentiation in treating primary liver cancer. MethodsForty-one patients with liver cancer were divided into the treated group and the control group. To the treated group turmeric oil microballoon, cinobufotalin, Aidi injection and iodized oil were given via hepatic artery perfusion/embolization, and to the control group chemotherapeutic agents and iodized oil were given for instead. Besides, both groups were given Chinese herbs according to TCM Syndrome Differentiation additionally. ResultsThe tumor inhibitory rate in the treated group and the control group was 77.78% and 69.57% respectively, with insignificant difference between them. The improvement of fatigue and anorexia in the treated group was better than that in the control group (P<0.05). The 6-month, 12-month and 24-month survival rate in the treated group and control group was 61.11% vs 56.62%, 27.78% vs 30.43% and 22.22% vs 26.09%, respectively, the difference between the two groups was insignificant. The occurrence of adverse reactions such as decreasing of white blood cells, platelet and hemoglobin, nausea and vomiting were obviously lower in the treated group than those in the control group (P<0.05). ConclusionChinese anti-cancer medicinal perfusion/embolization has affirmative short-term clinical effect in treating primary liver cancer with few adverse reactions, which was tolerable to patients, but its long-term clinical efficacy needs further observation.